Ken Song

Founder & CEO

Founder, Chairman, President and CEO of Candid Therapeutics. Previously founded RayzeBio (sold to Bristol Myers Squibb for $4.1B in 2024). MD.

Overview

Companies
1
Roles
Founder & CEO

Companies

1 company
Candid Therapeutics $875M
Private Founder & CEO

Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb.

Founder data is compiled from company records, public announcements, and verified sources. Roles reflect current or most recent known positions.